{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T10:40:55Z","timestamp":1791196855479,"version":"4.1.0"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,11,30]],"date-time":"2014-11-30T00:00:00Z","timestamp":1417305600000},"content-version":"vor","delay-in-days":2404,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2008,5]]},"DOI":"10.1111\/j.1469-0691.2008.01984.x","type":"journal-article","created":{"date-parts":[[2008,4,22]],"date-time":"2008-04-22T15:25:42Z","timestamp":1208877942000},"page":"71-83","source":"Crossref","is-referenced-by-count":62,"special_numbering":"S4","title":["Liposomal amphotericin B: what is its role in 2008?"],"prefix":"10.1016","volume":"14","author":[{"given":"F.","family":"Lanternier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Lortholary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/j.1469-0691.2008.01984.x_bib1","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1128\/JCM.00409-07","article-title":"Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing","volume":"45","author":"Pfaller","year":"2007","journal-title":"J Clin Microbiol"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib2","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1086\/342300","article-title":"Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989\u20131999","volume":"35","author":"Trick","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib3","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s10096-004-1103-y","article-title":"Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study","volume":"23","author":"Tortorano","year":"2004","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib4","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1128\/JCM.42.4.1519-1527.2004","article-title":"Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program","volume":"42","author":"Hajjeh","year":"2004","journal-title":"J Clin Microbiol"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib5","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1128\/AAC.46.6.1723-1727.2002","article-title":"In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp","volume":"46","author":"Pfaller","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib6","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa021585","article-title":"Comparison of caspofungin and amphotericin B for invasive candidiasis","volume":"347","author":"Mora-Duarte","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib7","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/S0140-6736(05)67490-9","article-title":"Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial","volume":"366","author":"Kullberg","year":"2005","journal-title":"Lancet"},{"issue":"suppl B","key":"10.1111\/j.1469-0691.2008.01984.x_bib8","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/jac\/28.suppl_B.73","article-title":"Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients","volume":"28","author":"Ringden","year":"1991","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib9","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/00006454-199802000-00013","article-title":"Liposomal amphotericin B treatment for neonatal fungal infections","volume":"17","author":"Scarcella","year":"1998","journal-title":"Pediatr Infect Dis J"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib10","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s150100070040","article-title":"Liposomal amphotericin B (AmBisome) in the treatment of neonatal candidiasis in very low birth weight infants","volume":"28","author":"Juster-Reicher","year":"2000","journal-title":"Infection"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib11","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1093\/jac\/dkg419","article-title":"Treatment of candidaemia in premature infants: comparison of three amphotericin B preparations","volume":"52","author":"Linder","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib12","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(07)60605-9","article-title":"Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial","volume":"369","author":"Kuse","year":"2007","journal-title":"Lancet"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib13","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1086\/317451","article-title":"A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph\/ABLC Collaborative Study Group","volume":"31","author":"Wingard","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib14","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1086\/376634","article-title":"Amphotericin B: time for a new \u2018gold standard\u2019","volume":"37","author":"Ostrosky-Zeichner","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib15","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1086\/380796","article-title":"Guidelines for treatment of candidiasis","volume":"38","author":"Pappas","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib16","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S1473-3099(03)00580-2","article-title":"British Society for Medical Mycology proposed standards of care for patients with invasive fungal infections","volume":"3","author":"Denning","year":"2003","journal-title":"Lancet Infect Dis"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib17","article-title":"Conference de conscensus prise en charge des candidoses et des aspergilloses invasives 2004","author":"Bretagne","year":"2004","journal-title":"Med Mal Infect"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib18","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib19","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1086\/497126","article-title":"Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome","volume":"41","author":"Patterson","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib20","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1046\/j.1365-2141.1998.00944.x","article-title":"Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections","volume":"103","author":"Leenders","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib21","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1086\/515033","article-title":"An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis","volume":"27","author":"Ellis","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib22","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1128\/AAC.45.12.3487-3496.2001","article-title":"Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study","volume":"45","author":"Walsh","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib23","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1086\/514341","article-title":"Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)","volume":"44","author":"Cornely","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib24","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1439-0507.2007.01362.x","article-title":"Liposomal amphotericin B (AmBisome) efficacy in confirmed invasive aspergillosis and other filamentous fungal infections in immunocompromised hosts: a pooled analysis","volume":"50","author":"Cordonnier","year":"2007","journal-title":"Mycoses"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib25","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1086\/313752","article-title":"Practice guidelines for the management of patients with histoplasmosis. Infectious Diseases Society of America","volume":"30","author":"Wheat","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib26","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/jac\/43.3.321","article-title":"Endemic mycoses: a treatment update","volume":"43","author":"Lortholary","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib27","doi-asserted-by":"crossref","first-page":"105","DOI":"10.7326\/0003-4819-137-2-200207160-00008","article-title":"Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS","volume":"137","author":"Johnson","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib28","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1128\/AAC.45.8.2354-2357.2001","article-title":"Clearance of fungal burden during treatment of disseminated histoplasmosis with liposomal amphotericin B versus itraconazole","volume":"45","author":"Wheat","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib29","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/S0140-6736(04)16301-0","article-title":"Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial","volume":"363","author":"Brouwer","year":"2004","journal-title":"Lancet"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib30","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1371\/journal.pmed.0040021","article-title":"Determinants of disease presentation and outcome during cryptococcosis: the CryptoA\/D study","volume":"4","author":"Dromer","year":"2007","journal-title":"PLoS Med"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib31","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1086\/313757","article-title":"Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America","volume":"30","author":"Saag","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib32","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1097\/00002030-199712000-00010","article-title":"Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis","volume":"11","author":"Leenders","year":"1997","journal-title":"AIDS"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib33","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/jac\/dkg020","article-title":"In vitro susceptibilities of zygomycetes to conventional and new antifungals","volume":"51","author":"Dannaoui","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib34","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1128\/AAC.47.11.3647-3650.2003","article-title":"Activity of posaconazole in treatment of experimental disseminated zygomycosis","volume":"47","author":"Dannaoui","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib35","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1128\/AAC.50.1.126-133.2006","article-title":"Posaconazole as salvage therapy for zygomycosis","volume":"50","author":"Greenberg","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib36","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1086\/500212","article-title":"Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases","volume":"42","author":"van Burik","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib37","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S1473-3099(05)70297-8","article-title":"Posaconazole: a broad-spectrum triazole antifungal","volume":"5","author":"Torres","year":"2005","journal-title":"Lancet Infect Dis"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib38","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/j.1368-5031.2004.00167.x","article-title":"Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections","volume":"58","author":"Herbrecht","year":"2004","journal-title":"Int J Clin Pract"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib39","first-page":"207","article-title":"Mucormycosis in hematologic patients","volume":"89","author":"Pagano","year":"2004","journal-title":"Haematologica"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib40","first-page":"1068","article-title":"Mucormycosis in hematologic malignancies: an emerging fungal infection","volume":"85","author":"Nosari","year":"2000","journal-title":"Haematologica"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib41","first-page":"101","article-title":"Diagnosis of invasive fungal infections: advances in nonculture systems","volume":"18","author":"Walsh","year":"1998","journal-title":"Curr Clin Top Infect Dis"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib42","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1007\/s100960100528","article-title":"Treatment of 21 cases of invasive mucormycosis with amphotericin B colloidal dispersion","volume":"20","author":"Herbrecht","year":"2001","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib43","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1080\/003655401300077469","article-title":"Liposomal amphotericin B and surgery in the successful treatment of invasive pulmonary mucormycosis in a patient with acute T-lymphoblastic leukemia","volume":"33","author":"Bjorkholm","year":"2001","journal-title":"Scand J Infect Dis"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib44","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1053\/jinf.2000.0397","article-title":"Zygomycosis in relapsed acute leukaemia","volume":"41","author":"Parkyn","year":"2000","journal-title":"J Infect"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib45","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/0002-9343(89)90441-5","article-title":"Empiric antifungal therapy in febrile granulocytopenic patients","volume":"86","author":"EORTC International Antimicrobial Therapy Cooperative Group","year":"1989","journal-title":"Am J Med"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib46","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0002-9343(82)90594-0","article-title":"Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia","volume":"72","author":"Pizzo","year":"1982","journal-title":"Am J Med"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib47","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1086\/496927","article-title":"Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study","volume":"41","author":"Maertens","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib48","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJM199903113401004","article-title":"Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group","volume":"340","author":"Walsh","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib49","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJM200201243460403","article-title":"Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever","volume":"346","author":"Walsh","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib50","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1056\/NEJMoa040446","article-title":"Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia","volume":"351","author":"Walsh","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib51","doi-asserted-by":"crossref","first-page":"5395","DOI":"10.1128\/JCM.43.10.5395-5396.2005","article-title":"Breakthrough Candida krusei fungemia during fluconazole prophylaxis followed by breakthrough zygomycosis during caspofungin therapy in a patient with severe aplastic anemia who underwent stem cell transplantation","volume":"43","author":"Girmenia","year":"2005","journal-title":"J Clin Microbiol"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib52","doi-asserted-by":"crossref","first-page":"E35","DOI":"10.1086\/341305","article-title":"Breakthrough trichosporonosis in a bone marrow transplant recipient receiving caspofungin acetate","volume":"35","author":"Goodman","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib53","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1034\/j.1399-3062.2002.02008.x","volume":"4","author":"Safdar","year":"2002","journal-title":"Transpl Infect Dis"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib54","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s15010-005-5082-4","article-title":"Breakthrough invasive infection due to Debaryomyces hansenii (teleomorph Candida famata) and Scopulariopsis brevicaulis in a stem cell transplant patient receiving liposomal amphotericin B and caspofungin for suspected aspergillosis","volume":"33","author":"Wagner","year":"2005","journal-title":"Infection"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib55","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1128\/JCM.43.9.4902-4904.2005","article-title":"Breakthrough disseminated Aspergillus ustus infection in allogeneic hematopoietic stem cell transplant recipients receiving voriconazole or caspofungin prophylaxis","volume":"43","author":"Pavie","year":"2005","journal-title":"J Clin Microbiol"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib56","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1093\/jac\/dki473","article-title":"Fluconazole for the management of invasive candidiasis: where do we stand after 15 years?","volume":"57","author":"Charlier","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib57","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa061098","article-title":"Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease","volume":"356","author":"Ullmann","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib58","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib59","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ijantimicag.2007.10.001","article-title":"Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study","volume":"31","author":"Cordonnier","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib60","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/sj.bmt.1705592","article-title":"High-dose weekly liposomal amphotericin B antifungal prophylaxis following reduced-intensity conditioning allogeneic stem cell transplantation","volume":"39","author":"El-Cheikh","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib61","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/pbc.21239","article-title":"Liposomal amphotericin B prophylaxis of invasive mold infections in children post allogeneic stem cell transplantation","volume":"50","author":"Roman","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib62","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1473-3099(05)70296-6","article-title":"Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980\u20132004","volume":"5","author":"Olliaro","year":"2005","journal-title":"Lancet Infect Dis"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib63","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1136\/bmj.323.7310.419","article-title":"Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial","volume":"323","author":"Sundar","year":"2001","journal-title":"BMJ"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib64","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1093\/clinids\/22.6.938","article-title":"Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome)","volume":"22","author":"Davidson","year":"1996","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib65","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1086\/377542","article-title":"Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study","volume":"37","author":"Sundar","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib66","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1093\/jac\/dkg356","article-title":"Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study","volume":"52","author":"Laguna","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib67","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1056\/NEJM199707033370103","article-title":"Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group","volume":"337","author":"van der Horst","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1469-0691.2008.01984.x_bib68","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1086\/432579","article-title":"Epidemiology and outcome of zygomycosis: a review of 929 reported cases","volume":"41","author":"Roden","year":"2005","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X14616190?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X14616190?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,10]],"date-time":"2019-05-10T12:26:32Z","timestamp":1557491192000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X14616190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5]]},"references-count":68,"alternative-id":["S1198743X14616190"],"URL":"https:\/\/doi.org\/10.1111\/j.1469-0691.2008.01984.x","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2008,5]]}}}